S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ABOS Acumen Pharmaceuticals Inc

1.25

0.01 (0.81%)

08 Mar 2025 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Acumen Pharmaceuticals Charts.

Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Acumen Pharmaceuticals Charts.

Acumen Pharmaceuticals Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Friday 24 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 24 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 24 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 24 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 24 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Friday 24 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 January 2025 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 January 2025 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 January 2025 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 January 2025 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Wednesday 22 January 2025 (2 months ago) • Edgar (US Regulatory)

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Friday 10 January 2025 (2 months ago) • GlobeNewswire Inc.

More Acumen Pharmaceuticals Inc News Articles

AUD vs US Dollar

Westpac Banking

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions